Results 41 to 50 of about 114,558 (301)
Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations
Pharmaceutics, 2023 Long-acting injectable (LAI) formulations promise to deliver patient benefits by overcoming issues associated with non-adherence. A preclinical assessment of semi-solid prodrug nanoparticle (SSPN) LAI formulations of emtricitabine (FTC) is reported here.
Paul Curley +16 more
doaj +1 more source
The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review [PDF]
, 2014 INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the ...
McGill, Janet B
core +2 more sources
Nephrectomized and Hepatectomized Animal Models as Tools in Preclinical Pharmacokinetics [PDF]
Basic & Clinical Pharmacology & Toxicology, 2013 AbstractEarly understanding of the pharmacokinetics and metabolic patterns of new drug candidates is essential for selection of optimal candidates to move further in to the drug development process.In vitromethodologies can be used to investigate metabolic patterns, but in general, they lack several aspects of the whole‐body physiology.
Vestergaard, Bill +2 more
openaire +3 more sources
Molecular Therapy: Methods & Clinical DevelopmentInduced pluripotent stem cells (iPSCs) have substantial transformative potential in regenerative medicine, enabling tissue repair and restoration.
Miyu Nakayama +5 more
doaj +1 more source
A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. [PDF]
, 2016 Acute myeloid leukemia (AML) cells meet the higher energy, metabolic, and signaling demands of the cell by increasing mitochondrial biogenesis and mitochondrial protein translation.
Brandwein, Joseph +14 more
core +1 more source
mAbsThe surge in the clinical use of therapeutic antibodies has reshaped the landscape of pharmaceutical therapy for many diseases, including rare and challenging conditions.
Ruoxuan Sun, Mark G. Qian, Xiaobin Zhang
doaj +1 more source
The Price of Progress: Funding and Financing Alzheimer\u27s Disease Drug Development [PDF]
, 2018 Introduction Advancing research and treatment for Alzheimer\u27s disease (AD) and the search for effective treatments depend on a complex financial ecosystem involving federal, state, industry, advocacy, venture capital, and philanthropy funding ...
Cummings, Jeffrey +2 more
core +2 more sources
Organizing of pharmacokinetic investigations
Фармакокинетика и Фармакодинамика, 2022 The paper is devoted to various aspects of the organization of drug pharmacokinetics research both at the preclinical and clinical levels (bioequivalence study, therapeutic drug monitoring, optimization of dosage regimens), as well as the arrangement of ...
I. I. Miroshnichenko, O. Y. Kravtsova
doaj +1 more source
Fluoxetine: a case history of its discovery and preclinical development [PDF]
, 2014 Introduction: Depression is a multifactorial mood disorder with a high prevalence worldwide. Until now, treatments for depression have focused on the inhibition of monoaminergic reuptake sites, which augment the bioavailability of monoamines in the CNS ...
Bel N +20 more
core +2 more sources
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source